Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery

Therapeutic Delivery

Volumn 3, Issue 3, 2012, Pages 389-404

  Yanes, Rolando E ^a   Tamanoi, Fuyuhiko ^a  

^a CALIFORNIA NANOSYSTEMS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; IDARUBICIN; LIPID; LIPOSOME; MESOPOROUS SILICA NANOPARTICLE; METAL; NANOPARTICLE; NC 6004; PACLITAXEL; PHOSPHONIC ACID DERIVATIVE; POLYMER; TOPOTECAN; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BREAST CANCER; CANCER INHIBITION; CELL LABELING; CELL TRANSPORT; CONTROLLED DRUG RELEASE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME RELEASE; EXOCYTOSIS; HUMAN; INTERMETHOD COMPARISON; INTRACELLULAR SIGNALING; LIGHT INTENSITY; LIPOSOMAL DELIVERY; MAGNETIC FIELD; NANOCHEMISTRY; NANOENCAPSULATION; NANOFABRICATION; NANOPHARMACEUTICS; NEOPLASM; NONHUMAN; OXIDATION REDUCTION REACTION; PARTICLE SIZE; PH MEASUREMENT; POROSITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SURFACE CHARGE; SURFACE PROPERTY;

EID: 84858126759     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.9     Document Type: Review

References (87)

1. Feynman R. Miniaturization. Gilbert HD (Ed.). Reinhold, N.Y., 282-296 (1961).
2. Drexler KE. Molecular engineering: an approach to the development of general capabilities for molecular manipulation. Proc. Natl Acad. Sci. USA 78(9), 5275-5278 (1981). (Pubitemid 12243534)
3. Manzano M, Collila M, Vallet-Regi M. Drug delivery from ordered mesoporous matrices. Expert Opin. Drug Deliv. 6, 1383-1400 (2009).
4. Vialpando M, Aerts A, Persoons J, Martens J, Van den Mooter G. Evaluation of ordered mesoporous silica as a carrier for poorly soluble drugs: influence of pressure on the structure and drug release. J. Pharm. Sci. 100, 3411-3420 (2011).
5. Qian KK, Bogner RH. Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems. J. Pharm. Sci. 101(2), 444-463 (2011).
6. Vialpando M, Martens JA, Van den Mooter G. Potential of ordered mesoporous silica for oral delivery of poorly soluble drugs. Therapeutic Delivery 2, 1079-1091 (2011).
7. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliv. Rev. 60, 1278-1288 (2008).
8. Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3, 1341-1346 (2007). (Pubitemid 47245524)
9. Bagwe RP, Hilliard LR, Tan W. Surface modifications of silica nanoparticles to reduce aggregation and nonspecific binding. Langmuir 22, 4357-4362 (2006).
10. Slowing I, Trewyn BG, Lin VS. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. J. Am. Chem. Soc. 128, 14792-14793 (2006). (Pubitemid 44851603)
11. Liong M, Lu J, Kovochich M et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2, 889-896 (2008).
12. Brevet D, Gary-Bobo M, Raehm L et al. Mannose targeted mesoporous silica nanoparticles for photodynamic therapy. Chem. Commun. 12, 1475-1477 (2009).
13. Ferris DP, Lu J, Gothard C et al. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small 7, 1816-1826 (2011).
14. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. (1990)21, 50-54 (1991).
15. Gary-Bobo M, Mir Y, Rouxel C et al. Mannose-functionalized mesoporous silica nanoparticles for efficient two-photon photodynamic therapy of solid tumors. Angew. Chem. Int. Ed. 50, 1-6 (2011).
16. Lu J, Liong M, Sherman S et al. Mesoporous silica nanoparticles for cancer therapy: energy-dependent cellular uptake and delivery of paclitaxel to cancer cells. Nanobiotechnology 3, 89-95 (2007).
17. Huang DM, Hung Y, Ko BS et al. Highly efficient celular labeling of mesoporous nanoparticles in human mesenchymal stem cells: implication for stem cell tracking. FASEB J. 19, 2014-2016 (2005). (Pubitemid 41759749)
18. Lu F, Wu SH, Hung Y, Mou CY. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small 5, 1408-1413 (2009).
19. Huang X, Teng X, Chen D, Tang F, He J. The effect of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 31, 438-448 (2010).
20. Slowing II, Vivero-Escoto JL, Zhao Y et al. Exocytosis of mesoporous silica nanoparticles from mammalian cells: from asymmetric cell-to-cell transfer to protein harvesting. Small 7, 1526-1532 (2011).
21. Hudson SP, Padera RF, Langer R, Kohane DS. The biocompatibility of mesoporous silicates. Biomaterials 29, 4045-4055 (2008).
22. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles, for cancer therapy in animals. Small 6(16), 1794-1805 (2010).
23. Souris JS, Lee CH, Cheng SH et al. Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials 31, 5564-5574 (2010).
24. Huang X, Li L, Liu T et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano. 5, 5390-5399 (2011).
25. Lu J, Li Z, Zink JI, Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine 8(2), 212-220 (2012).
26. He X, Nie H, Wang K, Tan W, Wu X, Zhang P. In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles. Anal. Chem. 80, 9597-9603 (2008).
27. Mamaeva V, Rosenholm JM, Bate-Eya LT et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of notch signaling in cancer. Mol. Ther. 19, 1538-1546 (2011).
28. He Q, Zhang Z, Gao F, Li Y, Shi J. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 7, 271-280 (2011).
29. Meng H, Xue M, Xia T et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano. 5, 4131-4144 (2011).
30. Ambrogio MW, Thomas CR, Zhao YL, Zink JI, Stoddart JF. Mechanized silica nanoparticles: a new frontier in theranostics nanomedicine. Acc. Chem. Res. 44, 903-913 (2011).
31. Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat. Rev. Mol. Cell Biol. 8, 622-632 (2007). (Pubitemid 47106614)
32. Angelos S, Khashab NM, Yang YW et al. pH clock-operated mechanized nanoparticles. J. Am. Chem. Soc. 131, 12912-12914 (2009).
33. Mock WL, Pierpont J. A curcubituril based molecular switch. J. Chem. Soc. Chem. Commun. 1990(2), 1509-1511 (1990).
34. Meng H, Xue M, Xia T et al. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensing nanovalves. J. Am. Chem. Soc. 132(36), 12690-12697 (2010).
35. Zhao Y, Li Z, Kabehie S, Bostros YY, Stoddart JF, Zink JI. pH-operated nanopistons on the surfaces of mesoporous silica nanoparticles. J. Am. Chem. Soc. 132, 13016-13025 (2010).
36. Lee CH, Cheng SH, Huang IP et al. Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. Angew. Chem. Int. Ed. 49, 8214-8219 (2010).
37. Patel K, Angelos S, Dichtel WR et al. Enzyme-responsive snap-top covered silica nanocontainers. J. Am. Chem. Soc. 130, 2382-2383 (2008). (Pubitemid 351304722)
38. Singh N, Karambelkar A, Gu L et al. Bioresponsive mesoporous silica nanoparticles for triggered drug release. J. Am. Chem. Soc. 133, 19582-19585 (2011).
39. Ambrogio MW, Pecorelli TA, Patel K et al. Snap-top nanocarriers. Org. Lett. 12, 3304-3307 (2010).
40. Meister A, Anderson ME. Glutathione. Annu. Rev. Biochem. 52, 711-760 (1983).
41. Sauer AM, Schlossbauer A, Ruthardt N, Cauda V, Bein T, Brauchle C. Role of endosomal escape for disulfide-based drug delivery from colloidal mesoporous silica evaluated by live-cell imaging. Nano. Lett. 10, 3684-3691 (2010).
42. Lu J, Choi E, Tamanoi F, Zink JI. Light-activated nanoimpeller-controlled drug release in cancer cells. Small 4, 421-426 (2008). (Pubitemid 351641616)
43. Ferris DP, Zhao YL, Khashab NM, Khatib HA, Stoddart JF, Zink JI. Light-operated mechanized nanoparticles. J. Am. Chem. Soc. 131, 1686-1688 (2009).
44. Sanchez AM, de Rossi RH. Effect of b-cyclodextrin on the thermal cis-trans isomerization of azobenzenes. J. Org. Chem. 61, 3446-3451 (1996). (Pubitemid 126575793)
45. Zhao YL, Stoddart JF. Azobenzene-based light-responsive hydrogel system. Langmuir 25, 8442-8446 (2009).
46. Knezevic NZ, Trewyn BG, Lin VS. Functionalized mesoporous silica nanoparticles-based visible light responsive controlled release delivery system. Chem. Commun. 47, 2817-2819 (2011).
47. Knezevic NZ, Trewyn BG, Lin VS. Light-and pH-responsive release of doxorubicin from a mesoporous silica-based nanocarrier. Chem. Eur. J. 17, 3338-3342 (2011).
48. Thomas CR, Ferris DP, Lee JH et al. Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. J. Am. Chem. Soc. 132, 10623-10625 (2010).
49. Ruiz-Hernandez E, Baeza A, Vallet-Regi M. Smart drug delivery through DNA/magnetic nanoparticle gates. ACS Nano. 5, 1259-1266 (2011).
50. Liu R, Zhao X, Wu T, Feng P. Tunable redox-responsive hybrid nanogated ensembles. J. Am. Chem. Soc. 130, 14418-14419 (2008).
51. Liu R, Zhang Y, Feng P. Multiresponsive supramolecular nanogated ensembles. J. Am. Chem. Soc. 131, 15128-15129 (2009).
52. Zhu CL, Song XY, Zhou WH, Yang HH, Wen YH, Wang XR. An efficient cell-targeting and intracellular controlled-release drug delivery system based on MSN-PEM-aptamer conjugates. J. Mater. Chem. 19, 7765-7770 (2009).
53. Wang LS, Wu LC, Lu SY et al. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding. ACS Nano. 4, 4371-4379 (2010).
54. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. Nat. Mater. 4, 435-446 (2005). (Pubitemid 40774047)
55. Alivisatos AP, Gu WW, Larabell C. Quantum dots as celular probes. Annu. Rev. Biomed. Eng. 7, 55-76 (2005).
56. Celik A, Comelekoglu U, Yalin S. A study on the investigation of cadmium chloride genotoxicity in rat bone marrow using micronucleus test and chromosome aberration analysis. Toxicol. Ind. Health 21, 243-248 (2005). (Pubitemid 43088277)
57. Pan J, Wan D, Gong J. PEGylated liposome coated QDs/mesoporous silica core-shell nanoparticles for molecular imaging. Chem. Commun. 47, 3442-3444 (2011).
58. Caravan P. Strategies for increasing the sensitivity of Gadolinium based MRI contrast agents. Chem. Soc. Rev. 35, 512-523 (2006). (Pubitemid 43815285)
59. Sitharaman B, Kissell KR, Hartman KB et al. Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem. Commun. 31, 3915-3917 (2005). (Pubitemid 41206205)
60. Zhang CF, Jugold M, Woenne EC et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using clinical 1.5T magnetic resonance scanner. Cancer Res. 67, 1555-1562 (2007). (Pubitemid 46383379)
61. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 63, 8122-8125 (2003). (Pubitemid 37549457)
62. Na HB, An K, Park Y et al. Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew. Chem. Int. Ed. 46, 5397-5401 (2007). (Pubitemid 47067643)
63. Carniato F, Tei L, Cossi M, Marchese L, Botta M. A chemical strategy for the relaxitivity enhancement of Gd(III) chelates anchored on mesoporous silica nanoparticles. Chemistry 16, 10727-10734 (2010).
64. Hsiao JK, Tsai CP, Chung TH et al. Mesoporous silica nanoparticles as a delivery system of gadolinium for effective human stem cell tracking. Small 4, 1445-1452 (2008).
65. Taylor KML, Kim JS, Rieter WJ, An H, Lin W, Lin W. Mesoporou silica nanospheres as highly efficient MRI contrast agents. J. Am. Chem. Soc. 130, 2154-2155 (2008). (Pubitemid 351287981)
66. Lee JE, Lee N, Kim H et al. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J. Am. Chem. Soc. 132, 552-557 (2010).
67. Kim T, Momin E, Choi J et al. Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells. J. Am. Chem. Soc. 133, 2955-2961 (2011).
68. Kim S, Kim H, Lee N et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonace and fluorescence imaging and for drug delivery. Angew. Chem. Int. Ed. 47, 8438-8441 (2008).
69. Kim S, Lim YT, Soltesz EG et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol. 22, 93-97 (2003).
70. MacLachlan I. Liposomal formulations for nucleic acid delivery. In: Antisense Drug Technology: Principles, Strategies, and Applications. Crooke ST (Ed.). CRC Press, Boca Raton , FL, USA, 237-270 (2008).
71. Drummond DC, Noble CO, Guo Z et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J. Control Release 141, 13-21 (2010).
72. Jain AK, Das M, Swarnakar NK, Jain S. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Crit. Rev. Ther. Drug Carrier Syst. 28(1), 1-45 (2011).
73. Leroux J-C, Allemann E, De Jaghere F, Doelker E, Gurny R. Biodegradable nanoparticles: from sustained release formulations to improved site specific drug delivery. J. Control Release 39, 339 (1996).
74. Tiyaboonchai W. Chitosan nanoparticles: a promising system for drug delivery. Naresuan Univ. J. 11, 51 (2003).
75. Oppenhiem RC. Paclitaxel loaded gelatin nanoparticles for intravesical bladder cancer therapy. Int. J. Pharm. 8, 217 (1981).
76. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surfaces B: Biointerfaces 75, 1-18 (2010).
77. Katakoa K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47, 113-131 (2001). (Pubitemid 32209236)
78. Matsumura Y. Polymeric micellar delivery systems in oncology. Jap. J. Clin. Oncol. 38, 793-802 (2008).
79. Lee KS, Chung HC, Im SA et al. Multicenter Phase II trial of Genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel in patients with metastatic breast cancer. Breast Cancer Res. Treat. 108, 241-250 (2008). (Pubitemid 351311357)
80. Xu C, Sun S. Superparamagnetic nanoparticles as targeted probes for diagnostic and therapeutic applications. Dalton Trans. 7, 5583-5591 (2009).
81. Sokolov K, Follen M, Aaron J et al. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res. 63, 1999-2004 (2003). (Pubitemid 36538596)
82. Loo C, Lowery A, Halas N, West J, Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano. Lett. 5, 709-711 (2005). (Pubitemid 40609745)
83. El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 239, 129-135 (2006). (Pubitemid 43946581)
84. Greiner NR, Phillips DS, Johnson JD, Volk F. Diamonds in detonation soot. Nature 333, 440-442 (1988).
85. Li J, Zhu Y, Li W, Zhang S, Peng Y, Huang Q. Nanodiamonds as intracellular transporters of chemotherapeutic drug. Biomaterials 31, 8410-8418 (2010).
86. Huang H, Pierstorff E, Osawa E, Ho D. Active nanodiamond hydrogels for chemotherapeutic delivery. Nano. Lett. 7, 3305-3314 (2007). (Pubitemid 350216021)
87. Rojas S, Gispert JD, Martin R et al. Biodistribution of amino-functionalized diamond nanoparticles. In vivo studies based on 18F radionuclide emission. ACS Nano. 5(7), 5552-5559 (2011).